Vinge has advised EQT IX in connection with its exit of Beijer Ref AB (publ)
Vinge has advised EQT IX (”EQT”) in connection with the sale of all of its remaining shares of serie…
CV
Practice Areas
Capital Markets and Public M&A, M&A, General Corporate
Sofie Bjärtun specialises in capital markets, public M&A, general corporate matters and corporate governance. She has broad experience from takeovers, IPOs, capital raisings and other capital markets transactions. Sofie also advises boards and management teams on corporate governance, disclosure and securities law matters on a continuous basis.
"Sofie is a class act and a true partner to her clients." Chambers & Partners 2026
Sofie Bjärtun is ranked as a Rising star partner in IFLR 1000 2023
Vinge is a full service business law firm with leading expertise within all areas of business law. We are a total of more than 550 co‑workers at our offices in Stockholm, Gothenburg, Malmö and Brussels.
https://www.vinge.se/en/our-people/sofie-bjartun/
Sofie Bjärtun specialises in capital markets, public M&A, general corporate matters and corporate governance. She has broad experience from takeovers, IPOs, capital raisings and other capital markets transactions. Sofie also advises boards and management teams on corporate governance, disclosure and securities law matters on a continuous basis.
Vinge has advised EQT IX (”EQT”) in connection with the sale of all of its remaining shares of serie…
Vinge represents Investor AB (publ) (“Investor”) in connection with Electrolux Group’s rights issue…
Vinge advises EQT AB on its acquisition Coller Capital, a global secondaries firm with nearly USD 50…
Vinge has advised EQT IX (”EQT”) in connection with the sale of shares in Beijer Ref AB (publ) throu…
OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies,…
Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox A…
EQT AB (publ) has issued senior bonds in the aggregate principal amount of USD 500,000,000 with an i…
Vinge has acted as advisor to Ambea AB (publ) together with the Finnish law firm Krogerus in connect…
24SevenOffice is a listed company (First North Stockholm) that provides modular software for account…
EQT X, through its indirectly owned subsidiary Oak BidCo S.à r.l., has secured an ownership of 72.5%…
Vinge has advised EQT IX (”EQT”) in connection with the sale of shares in Beijer Ref AB (publ) throu…
Vinge has advised SmartCella Holding AB in connection with its fund raising of EUR 50 million. The c…
In total, 7.6 million shares were placed at a price of SEK 64 per share, corresponding to a total va…
EQT Infrastructure VI, through its indirectly owned subsidiary Otello BidCo AB, announces a recommen…
In total, 7.7 million shares were placed at a price of SEK 57.50 per share, corresponding to a total…
In total, 8.4 million shares were placed at a price of SEK 43.50 per share, corresponding to a total…
Vinge has advised EQT IX (”EQT”) in connection with the sale of shares in Beijer Ref AB (publ) throu…
FCG Holding Sverige AB has announced a recommended public offer in cash to the shareholders of Trans…
EQT AB (publ) has completed the issuance of a EUR 750,000,000 sustainability-linked bond maturing in…
Vinge has advised EQT in connection with the combination with Baring Private Equity Asia, a leading…
Vinge acts as lead advisor to EQT AB in connection with its acquisition of Life Sciences Partners, a…
The loan agreement with the EIB grants Oncopeptides access to an unsecured loan facility of up to EU…
Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm…
The board of directors of Medicover has, on the basis of an authorisation granted from the annual ge…
Vinge advises Calliditas Therapeutics in connection with its capital raising and listing on The Nasd…
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…
Vinge has advised Industrifonden and Investinor in connection with a sale of in total approximately…
Vinge has advised EQT AB (publ) (“EQT”) in connection with the offering and listing on Nasdaq Stockh…
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…
Vinge advises Finanzero in connection with the company's capital raising of approximately SEK 100 mi…
In total, 1,2 million shares were placed at a price of SEK 148 per share, corresponding to a total v…
Vinge advises Calliditas Therapeutics AB (publ) (“Calliditas Therapeutics”) in connection with the l…
Vinge advises ABG Sundal Collier, Skandinaviska Enskilda Banken and Swedbank who are acting as Joint…
The board of directors of IRLAB Therapeutics has, on the basis of an authorisation granted from the…
Vinge advises Finanzero in connection with the company's capital raising of approximately SEK 30 mil…
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncop…
Vinge has advised Pandox Aktiebolag (publ) with certain financing and capital markets related questi…
Vinge assisted EQT V Limited (”EQT”) in connection with the sale of shares in AcadeMedia AB (publ) (…
Vinge advises DGC One AB (publ) (“DGC”) in connection with EQT’s acquisition of 85.2 percent of the…
Vinge advises Medicover AB (publ) (“Medicover”) and its main shareholder Celox Holding AB (“Celox”),…
"Sofie is a class act and a true partner to her clients." Chambers & Partners 2026
Sofie Bjärtun is ranked as a Rising star partner in IFLR 1000 2023
Advokat Sofie Bjärtun, advokat Rikard Lindahl, advokat Malin Malm Waerme and advokat Daniel Wendelss…